Current treatments of rheumatoid arthritis: From the 'NinJa' registry

Expert Review of Clinical Immunology

Volumn 8, Issue 5, 2012, Pages 455-465

  Saeki, Yukihiko ^a   Matsui, Toshihiro ^b   Saisho, Koichiro ^c   Tohma, Shigeto ^b  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^b SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^c NHO Miyakonojo Hospital   (Japan)

Author keywords

clinical database; Japan; NinJa; outcomes; rheumatoid arthritis; treatments

Indexed keywords

ABATACEPT; ACTARIT; ADALIMUMAB; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOMALATE; BUCILLAMINE; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB;

ARTHRODESIS; ARTHROPLASTY; CLINICAL DISEASE ACTIVITY INDEX; DATA BASE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28 ESR; DISEASE REGISTRY; DRUG COST; DRUG SAFETY; DRUG STRUCTURE; ERYTHROCYTE SEDIMENTATION RATE; GROUPS BY AGE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INCIDENCE; INFLAMMATION; JAPAN; JOINT PROSTHESIS; JOINT SURGERY; LEUKOPENIA; LIVER TOXICITY; OUTCOME ASSESSMENT; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMPLIFIED DISEASE ACTIVITY INDEX; SYNOVECTOMY; TENDON RECONSTRUCTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; HUMANS; JAPAN; METHOTREXATE; REGISTRIES; TREATMENT OUTCOME;

EID: 84865006181     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.35     Document Type: Review

References (41)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 373(9664), 659-672 (2009
2. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin. Pharmacol. Ther. 91(1), 30-43 (2012
3. Yazici Y. Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 28(5 Suppl. 61), S65-S67 (2010
4. ACR Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 46, 328-346 (2002
5. Saag KG, Teng GG, Patkar NM et al.; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762-784 (2008
6. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 372(9636), 375-382 (2008
7. Schoels M, Knevel R, Aletaha D et al. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search. Ann. Rheum. Dis. 69(4), 638-643 (2010
8. Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod. Rheumatol. 16(2), 75-76 (2006
9. Matsui T, Kuga Y, Kaneko A et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann. Rheum. Dis. 66(9), 1221-1226 (2007
10. Nishino J, Tanaka S, Matsui T et al. Prevalence of joint replacement surgery in rheumatoid arthritis patients: Crosssectional analysis in a large observational cohort in Japan. Mod. Rheumatol. 19(3), 260-264 (2009
11. Yasui T, Nishino J, Kadono Y et al. Impact of biologics on the prevalence of orthopedic surgery in the National Database of Rheumatic Diseases in Japan. Mod. Rheumatol. 20(3), 233-237 (2010
12. Matsui T, Kuga Y, Nishino J, Kaneko A, Eto Y, Tohma S. Comparison of composite disease activity indices for rheumatoid arthritis. Mod. Rheumatol. 21(2), 134-143 (2011
13. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31(3), 315-324 (1988
14. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62(9), 2569-2581 (2010
15. Van der Heide DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgement in clinical practice by rheumatologists. J. Rheumatol. 20, 579-581 (1993)
16. Smolen JS, Breedveld FC, Schiff MH et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42(2), 244-257 (2003
17. Aletaha D, Smolen JS. The simplified disease activity index (SDAI) and clinical disease activity index (CDAI) to monitor patients in standard clinical care. Best Pract. Res. Clin. Rheumatol. 21(4), 663-675 (2007
18. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355(7), 704-712 (2006
19. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: A systematic review of the literature. Ann. Rheum. Dis. 68(7), 1094-1099 (2009
20. Yamanaka H, Inoue E, Tanaka E et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: Evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod. Rheumatol. 17(2), 98-105 (2007
21. Yokota N, Kuga Y, Kanazawa T, Morishita M, Tanida K, Itou K. Ten years results of bucillamine in the treatment of rheumatoid arthritis. Mod. Rheumatol. 17(1), 33-36 (2007
22. Abe T, Takeuchi T, Miyasaka N et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol. 33(1), 37-44 (2006
23. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J. Rheumatol. 36(5), 898-906 (2009
24. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66(9), 1162-1167 (2007
25. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T; RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: Results from the RISING study. Mod. Rheumatol. 19(5), 478-487 (2009
26. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22), 1586-1593 (2000
27. Fevang BT, Lie SA, Havelin LI, Engesaeter LB, Furnes O. Reduction in orthopedic surgery among patients with chronic inflammatory joint disease in Norway, 1994-2004. Arthritis Rheum. 57(3), 529-532 (2007
28. Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 a0nd 2003: An indication of improved long-term outcomes of rheumatoid arthritis. Ann. Rheum. Dis. 66(3), 341-344 (2007
29. Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Ann. Rheum. Dis. 69, 868-871 (2010
30. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin. Exp. Rheumatol. 23(5 Suppl. 39), S100-S108 (2005
31. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum. 52(9), 2625-2636 (2005
32. Smolen JS, Aletaha D, Bijlsma JW et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann. Rheum. Dis. 69(4), 631-637 (2010
33. Takeuchi T, Miyasaka N, Tatsuki Y et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(7), 1208-1215 (2011
34. Dirven L, Visser K, Klarenbeek NB et al. Towards personalized treatment: Predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression. Scand. J. Rheumatol. 41(1), 15-19 (2012
35. Korpela M, Laasonen L, Hannonen P et al.; FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study. Arthritis Rheum. 50(7), 2072-2081 (2004
36. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 55(6), 864-872 (2006
37. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005
38. O'shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 3(7), 555-564 (2004
39. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60(7), 1895-1905 (2009
40. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58(11), 3309-3318 (2008
41. Ogasawara M, Tamura N, Onuma S et al. Observational cross-sectional study revealing less aggressive treatment in Japanese elderly than nonelderly patients with rheumatoid arthritis. J. Clin. Rheumatol. 16(8), 370-374 (2010